Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Clinical Pharmacy
CP-166
QUALITY PERCEIVED BY THE PATIENTS OF A PHARMACEUTICAL CARE CONSULTATION AND STEPS TAKEN TO IMPROVE IT
CP-163
ANALYSIS OF THE SIDE EFFECTS AND THE TREATMENT DISCONTINUATION OF DIMETHYL FUMARATE IN A TERTIARY HOSPITAL
CP-161
INCIDENCE OF ABNORMALITIES OF URINARY DIPSTICK TESTS IN PATIENTS RECEIVING BIOTHERAPIES
CP-160
CLINICAL PHARMACIST INTERVENTIONS IN THE CRITICAL PATIENT: EVOLUTION OF A 4 YEAR PROJECT
CP-159
DIRECT ACTING ANTIVIRALS (DAAS) FOR THE TREATMENT OF HCV INFECTION IN HIV/HCV COINFECTED PATIENTS: A CLINICAL EXPERIENCE
CP-158
UNCRITICAL USE OF PROTON PUMP INHIBITORS IN NON-INTENSIVE CARE UNITS OF A UNIVERSITY HOSPITAL
CP-157
ANALYSIS OF THE EXPENDITURE ON THE TREATMENT OF HEPATITIS C VIRUS IN 2015
CP-1566
PRESCRIBING PATTERN, TOLERABILITY AND EFFICACY STUDY (4 WEEKS) OF THE NOVEL DRUG ‘XIAPEX’
CP-155
USE AND SAFETY PROFILE OF ORAL MEDICATION BEFORE SECONDLINE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
CP-154
ACUTE CORONARY SYNDROME IN A PATIENT RECEIVING ROMIPLOSTIM
CP-152
APPLYING THE RESULTS FROM THE TOGA TRIAL INTO CLINICAL PRACTICE: DATA FROM THE AGAMENON MULTICENTRE STUDY
CP-149
REDESIGN OF THE MANAGEMENT MODEL AND PHARMACEUTICAL CARE OF PATIENTS WITH HEPATITIS C VIRUS INFECTION
CP-148
IMPACT ON DRUG ADHERENCE AND VIRAL LOAD AFTER PHARMACEUTICAL INTERVENTION IN SELECTED HEPATITIS B OUTPATIENTS
CP-146
DRUG INTERACTIONS WITH DIRECT ACTING ANTIVIRALS FOR HEPATITIS C: WHAT ABOUT IN PRACTICE? PHARMACEUTICAL IMPACT
CP-143
THE CHANGE IN USE OF CALCINEURIN INHIBITORS IN KIDNEY TRANSPLANT RECIPIENTS AND ITS EFFECT ON SHORT TERM GRAFT AND PATIENT OUTCOMES
Pages
« first
‹ previous
…
8
9
10
11
12
13
14
15
16
…
next ›
last »
Follow Us